KR
KRBP.US Kiromic Biopharma Inc
- Market cap
- USD 215K
- P/E
- -
- P/B
- 11.55x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is KRBP.US undervalued?
Graham numberThe Graham number of Kiromic Biopharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kiromic Biopharma Inc fundamental analysis
No fundamental analysis for Kiromic Biopharma Inc yet.
Kiromic Biopharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combi…
Full company profileKiromic Biopharma Inc financial statements
Kiromic Biopharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -80.9K | -87.5K | -200K | -470K | -2.07M | -2.80M | -8.07M |
| Operating Income | -3.18M | -3.71M | -19.2M | -25.7M | -31.1M | -19.9M | -23.8M |
| EBITDA | -3.10M | -3.62M | -19.0M | -25.1M | -32.9M | -16.3M | -28.4M |
| Net Income | -3.82M | -3.75M | -19.2M | -25.7M | -38.2M | -21.3M | -26.9M |
| EPS | -1.08 | -0.97 | -2.64 | -2.25 | -2.34 | -0.65 | -1.03 |
| Balance Sheet | |||||||
| Total Assets | 876K | 2.65M | 12.8M | 30.7M | 12.0M | 12.2M | 8.55M |
| Total Liabilities | 611K | 674K | 1.47M | 3.41M | 17.7M | 21.3M | 21.1M |
| Shareholders' Equity | 265K | 1.98M | 11.4M | 27.3M | -5.77M | -9.12M | -12.6M |
| Cash & Short-term Investments | 384K | 1.93M | 10.2M | 25.4M | 645K | 3.20M | 1.14M |
| Total Debt | - | - | 468K | 455K | 9.41M | 15.5M | 14.6M |
| Cash Flow | |||||||
| Operating Cash Flow | -2.15M | -2.91M | -6.13M | -20.3M | -23.7M | -21.2M | -19.5M |
| Capital Expenditure | 137K | 303K | 1.46M | 1.89M | 4.88M | 207K | 366K |
| Free Cash Flow | -2.29M | -3.22M | -7.58M | -22.2M | -28.6M | -21.4M | -19.8M |
| Ratios | |||||||
| ROE | -1,438.3% | -189.5% | -169.0% | -93.9% | - | - | - |
| ROA | -435.6% | -141.4% | -149.7% | -83.5% | -319.0% | -175.0% | -314.8% |
| Debt to Equity | - | - | 0.04x | 0.02x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kiromic Biopharma Inc dividends
Kiromic Biopharma Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:30 on Mar 13, 2023.
Who owns Kiromic Biopharma Inc
- Insiders 2.27%
- Institutions 0.00%
- Public & others 97.73%
- Shares outstanding 2.65M
- Free float 1.18M
Top funds holding KRBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity® NASDAQ Composite Index® | 1.22K | 0.10% | 0.00% | Aug 2023 |
| SSgA U.S. Extended Market Index Class I | 557.00 | 0.05% | +0.18% | Mar 2023 |
| SSgA U.S. Total Market Index Strategy | 175.00 | 0.01% | 0.00% | Mar 2023 |
| Fidelity® Extended Market Index | 143.00 | 0.01% | 0.00% | Aug 2023 |
| Spartan Extended Market Index Pool E | 1.00 | 0.00% | 0.00% | Aug 2023 |
Top institutions holding KRBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Motiv8 Investments LLC | 4.00 | 0.00% | 0.00% | Dec 2025 |
Kiromic Biopharma Inc company profile
- Company name
- Kiromic Biopharma Inc
- Ticker
- KRBP.US
- Exchange
- USA Stocks
- Listed since
- Oct 16, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- 7707 Fannin Street, Houston, TX, United States, 77054
- Phone
- 832 968 4888
- Website
- kiromic.com
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung cancer. It also develops Isocel, which is clinical trial in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; Procel, which is in clinical trial in combination with low-dose radiation to treat PD-L1 positive solid malignancies; ALEXIS-ISO-1, which is in clinical trial to evaluate Isocel in patients with Mesothelin Isoform 2 positive solid malignancies; and ALEXIS-PRO-1, which is in clinical trial to evaluate Procel in patients with PD-L1 positive solid malignancies. It has a license agreement with Longwood University. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. On March 21, 2025, Kiromic BioPharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Kiromic Biopharma Inc management
4- Mr. Pietro Bersani CPA, J.D.CEO & Director · born 1968
- Mr. Brian Hungerford CPA, CGMAChief Financial Officer · born 1976
- Dr. Leonardo Mirandola Ph.D.Chief Scientific Officer & COO · born 1982
- Dr. Scott Dahlbeck M.D., Pharm.D., PharmDChief of Staff · born 1962